Comparison of the efficacies of various formulations of amphotericin B against murine visceral leishmaniasis

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  1997-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/AAC.41.10.2089PMID 9333030PMCID PMC164075
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cure of antimony-unresponsive Indian visceral leishmaniasis with amphotericin B lipid complex.

  1996cited by this paper
• Amphotericin B Kills Unicellular Leishmanias by Forming Aqueous Pores Permeable to Small Cations and Anions

  1996cited by this paper
• Lipid formulations of amphotericin b in the treatment of experimental visceral leishmaniasis due to Leishmania infantum.

  1996cited by this paper
• Lipid Formulations of Amphotericin B

  1995cited by this paper
• Lipid formulations of amphotericin B. Less toxicity but at what economic cost?

  1995cited by this paper
• Efficacy of liposomal amphotericin B in the treatment of visceral leishmaniasis in patients coinfected with the human immunodeficiency virus.

  1995cited by this paper
• Amphotericin B nephrotoxicity: the adverse consequences of altered membrane properties.

  1995cited by this paper
• Efficacy of intermittent liposomal amphotericin B in the treatment of visceral leishmaniasis in patients infected with human immunodeficiency virus.

  1995cited by this paper
• Treatment of kala-azar in Brazil with Amphocil (amphotericin B cholesterol dispersion) for 5 days.

  1995cited by this paper
• Apparently successful treatment of two cases of post kala-azar dermal leishmaniasis with liposomal amphotericin B.

  1995cited by this paper
• Relapse of visceral leishmaniasis in patients who were coinfected with human immunodeficiency virus and who received treatment with liposomal amphotericin B.

  1994cited by this paper
• Treatment of Brazilian kala-azar with a short course of amphocil (amphotericin B cholesterol dispersion).

  1993cited by this paper
• Effects of aggregation and solvent on the toxicity of amphotericin B to human erythrocytes

  1992cited by this paper
• Liposomal and Lipid Formulations of Amphotericin B

  1992influential reference
• Effects of the aggregation state of amphotericin B on its toxicity to mice

  1992cited by this paper
• Liposomal amphotericin B in drug-resistant visceral leishmaniasis.

  1991cited by this paper
• Visceral Leishmaniasis: Drug Carrier System Characteristics and the Ability to Clear Parasites from the Liver, Spleen and Bone Marrow in Leishmania donovani Infected BALB/c Mice

  1989cited by this paper
• The limitations of carrier mediated sodium stibogluconate chemotherapy in the BALB/c mouse model of visceral leishmaniasis.

  1989cited by this paper
• Unusual lipid structures selectively reduce the toxicity of amphotericin B.

  1988cited by this paper
• The therapeutic effect of sodium stibogluconate in BALB/c mice infected with Leishmania donovani is organ‐dependent

  1988cited by this paper
• Therapy in man.

  1987cited by this paper
• Fate and behavior of liposomes in vivo: a review of controlling factors.

  1987cited by this paper
• A study of the inclusion complex of amphotericin-B with γ-cyclodextrin

  1986cited by this paper
• Clinical Pharmacokinetics of Systemic Antifungal Drugs

  1983cited by this paper
• Regulation of Leishmania populations within the host. I. the variable course of Leishmania donovani infections in mice.

  1977cited by this paper

• Characterization of a novel Leishmania antigen containing a repetitive domain and its potential use as a prophylactic and therapeutic vaccine

  2025cites this paper
• Chitosan-Coated PLGA Nanospheres for Improved Amphotericin B Delivery: Characterization, Mucoadhesion, and Cytotoxicity Assessment

  2024influential citation
• Visceral leishmaniasis in a 10-month-old Austrian girl Epidemiological Aspects and Treatment Strategies with review of the Iiterature

  2023cites this paper
• LEISH2b - A phase 2b study to assess the safety, efficacy, and immunogenicity of the Leishmania vaccine ChAd63-KH in post-kala azar dermal leishmaniasis

  2022cites this paper
• - Amphotericin B: A drug of choice for Visceral Leishmaniasis.

  2022cites this paper
• Alginate-amphotericin B nanocomplexes covered by nanocrystals from bacterial cellulose: physico-chemical characterization and in vitro toxicity

  2021cites this paper
• Self-assembling cashew gum-GRAFT-POLYLACTIDE copolymer nanoparticles as a potential amphotericin b delivery matrix.

  2020influential citation
• Preparation of Topical Nano Gel Loaded With Hesperidin Emusomoes: In vitro and in vivo Studies

  2020cites this paper
• Development of dextrin-amphotericin B formulations for the treatment of Leishmaniasis.

  2020cites this paper
• Nanocapsules of Sterculia striata acetylated polysaccharide as a potential monomeric amphotericin B delivery matrix.

  2019cites this paper
• Development of Amphotericin B-loaded Propionate Sterculia striata Polysaccharide Nanocarrier.

  2019cites this paper
• Amphotericin B‐albumin conjugates: Synthesis, toxicity and anti‐fungal activity

  2018cites this paper
• Pickering emulsion stabilized by cashew gum- poly-l-lactide copolymer nanoparticles: Synthesis, characterization and amphotericin B encapsulation.

  2018cites this paper
• Antifungal Efficacy of Amphotericin B against Dermatophytes and its Relevance in Recalcitrant Dermatophytoses: A Commentary

  2018cites this paper
• Oral administration of amphotericin B nanoparticles: antifungal activity, bioavailability and toxicity in rats

  2017influential citation
• Anti-fungal and anti-leishmanial activities of pectin-amphotericin B conjugates

  2017cites this paper
• Synthesis and evaluation of anti-fungal activities of sodium alginate-amphotericin B conjugates.

  2017cites this paper
• Nanostructured delivery systems with improved leishmanicidal activity: a critical review

  2017cites this paper
• A new nanoemulsion formulation improves antileishmanial activity and reduces toxicity of amphotericin B

  2017cites this paper
• Nanoarchitectures for Neglected Tropical Protozoal Diseases: Challenges and State of the Art

  2017cites this paper
• An Original Lipid Complex System for Amphotericin B

  2016cites this paper
• Nanocarriers Made from Non-Ionic Surfactants or Natural Polymers for Pulmonary Drug Delivery.

  2016cites this paper
• MACROPHAGE TARGETING: A STRATEGY FOR LEISHMANIASIS SPECIFIC DELIVERY

  2016cites this paper
• Self-assembled amphotericin B-loaded polyglutamic acid nanoparticles: preparation, characterization and in vitro potential against Candida albicans

  2015cites this paper
• Nanocarrier-based topical drug delivery for an antifungal drug

  2014cites this paper
• Poly(methacrylic acid) complexation of amphotericin B to treat neglected diseases

  2014cites this paper
• Significance of Algal Polymer in Designing Amphotericin B Nanoparticles

  2014cites this paper
• Amphotericin B microparticles ‘AmbiShell’ from phospholipid and gelatin: Development and investigation by combined DLS and SANS resolves the core‐shell structure

  2014cites this paper
• Formulation of Particulate-based Immunomodulatory Therapeutics for the Treatment of Diseases

  2014cites this paper
• Amphotericin B topical microemulsion: formulation, characterization and evaluation.

  2014cites this paper
• Noncovalent complexation of amphotericin-B with Poly(α-glutamic acid).

  2013cites this paper
• High performance liquid chromatography with evaporative light scattering detection for the characterisation of a vesicular delivery system during stability studies.

  2013cites this paper
• Parasite burden in Leishmania (Leishmania) amazonensis-infected mice: validation of luciferase as a quantitative tool.

  2013cites this paper
• Preparation and characterisation of amphotericin B-copolymer complex for the treatment of leishmaniasis

  2013cites this paper
• Therapeutic Vaccination With Recombinant Adenovirus Reduces Splenic Parasite Burden in Experimental Visceral Leishmaniasis

  2012cites this paper
• CHARACTERIZATION OF THE T CELL RESPONSE TO AMPHOTERICIN B

  2012cites this paper
• Erythrozyten als Drug Carrier für schwerlösliche Substanzen am Beispiel von Amphotericin B

  2012cites this paper
• The efficacy of aerosol treatment with non-ionic surfactant vesicles containing amphotericin B in rodent models of leishmaniasis and pulmonary aspergillosis infection.

  2012cites this paper
• Amphotericin B Lipid Complex

  2012cites this paper
• RETRACTED ARTICLE Development and evaluation of tripalmitin emulsomes for the treatment of experimental visceral leishmaniasis

  2012influential citation
• Drug delivery strategies for therapy of visceral leishmaniasis

  2010cites this paper
• Emerging role of vesicular carriers for therapy of visceral leishmaniasis: conventional versus novel.

  2010cites this paper
• Solid lipid nanoparticle (SLN) formulations as a potential tool for the reduction of cytotoxicity of saponins.

  2009cites this paper
• Poloxamers: A pharmaceutical excipients with therapeutic behaviors

  2009cites this paper
• Y SYSTEMS FOR THE TREATMENT AND PREVENTION OF LEISHMANIASIS TMENT AND PREVENTION OF LEISHMANIASIS TMENT AND PREVENTION OF LEISHMANIASIS TMENT AND PREVENTION OF LEISHMANIASIS TMENT AND PREVENTION OF LEISHMANIASIS

  2009cites this paper
• DELIVERY SYSTEMS FOR THE TREATMENT AND PREVENTION OF LEISHMANIASIS

  2009cites this paper
• Drug delivery systems against leishmaniasis? Still an open question

  2008cites this paper
• Amphotericin B formulations and drug targeting.

  2008cites this paper
• Delivery systems to increase the selectivity of antibiotics in phagocytic cells.

  2008cites this paper
• Drug delivery systems against leishmaniasis? Still an open question.

  2008cites this paper
• Effect of aggregation state on the toxicity of different amphotericin B preparations.

  2008cites this paper
• Cellular differentiation and antibiotic production by Streptomyces nodosus immobilised in alginate capsules

  2007cites this paper
• Amphotericin B-Gum Arabic Conjugates: Synthesis, Toxicity, Bioavailability, and Activities Against Leishmania and Fungi

  2007cites this paper
• Activity, toxicity and analysis of resistance of essential oil from Chenopodium ambrosioides after intraperitoneal, oral and intralesional administration in BALB/c mice infected with Leishmania amazonensis: a preliminary study.

  2007cites this paper
• Development and characterization of amphotericin B bearing emulsomes for passive and active macrophage targeting

  2007cites this paper
• Mixed micellar nanoparticle of amphotericin b and poly styrene-block-poly ethylene oxide reduces nephrotoxicity but retains antifungal activity

  2007cites this paper
• Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis.

  2006cites this paper
• Reduced renal toxicity of nanoparticular amphotericin B micelles prepared with partially benzylated poly-L-aspartic acid.

  2006cites this paper
• Amphotericin B

  2005cites this paper
• Synthesis of decapeptide of L-aspartic acid and benzyl-L-aspartic acid by solid phase peptide synthesis.

  2005cites this paper
• Influence of the vehicle on the properties and efficacy of microparticles containing amphotericin B

  2005cites this paper
• Synthesis of decapeptide ofl-aspartic acid and benzyl-l-aspartic acid by solid phase peptide synthesis

  2005cites this paper
• Luc Van in Hamsters Leishmania donovani Amphotericin B ( AmBisome ) against Saponin Maesabalide III and Liposomal Comparative Activities of the Triterpene

  2004cites this paper
• Treatment of Experimental Visceral Leishmaniasis with Amphotericin B in Stable Albumin Microspheres

  2004cites this paper
• Amphotericin B Molecular Organization as an Essential Factor to Improve Activity/Toxicity Ratio in the Treatment of Visceral Leishmaniasis

  2004cites this paper
• New lipid formulation of amphotericin B: spectral and microscopic analysis.

  2004cites this paper
• Anti‐leishmanial activity of a new formulation of amphotericin B

  2004cites this paper
• Comparative Activities of the Triterpene Saponin Maesabalide III and Liposomal Amphotericin B (AmBisome) against Leishmania donovani in Hamsters

  2004cites this paper
• Two doses of a lipid formulation of amphotericin B for the treatment of Mediterranean visceral leishmaniasis.

  2003cites this paper
• Treatment of leishmaniasis in HIV-positive patients

  2003cites this paper
• Polymeric carriers for amphotericin B: in vitro activity, toxicity and therapeutic efficacy against systemic candidiasis in neutropenic mice.

  2003cites this paper
• Delivery strategies for antiparasitics

  2003cites this paper
• Toxicity and Antileishmanial Activity of a New Stable Lipid Suspension of Amphotericin B

  2003cites this paper
• Antifungal drug therapy in avian species.

  2003cites this paper
• In vitro antileishmanial activity of amphotericin B loaded in poly(epsilon-caprolactone) nanospheres.

  2002cites this paper
• In Vitro Antileishmanial Activity of Amphotericin B Loaded in Poly(ε-Caprolactone) Nanospheres

  2002cites this paper
• [Recent findings on the treatment of leishmaniasis].

  2001cites this paper
• No evidence of oxidant events in amphotericin B cytotoxicity versus L. infantum promastigotes.

  2001cites this paper
• Clinical and Experimental Advances in Treatment of Visceral Leishmaniasis

  2001cites this paper
• Clinical and Experimental Advances in Treatment of Visceral Leishmaniasis

  2001cites this paper
• Treatment of Visceral Leishmaniasis with Sterically Stabilized Liposomes Containing Camptothecin

  2001cites this paper
• N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers for targeted delivery of 8-aminoquinoline antileishmanial drugs.

  2001cites this paper
• Distribution of Lipid Formulations of Amphotericin B into Bone Marrow and Fat Tissue in Rabbits

  2000cites this paper
• In Vitro Reversion of Amphotericin B Resistance in Leishmania donovani by Poloxamer 188

  2000cites this paper
• Lipid-based formulations of amphotericin B.

  2000cites this paper
• Efficacy of amphotericin B colloidal dispersion in the treatment of Mediterranean visceral leishmaniasis in immunocompetent adult patients.

  2000cites this paper
• A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis.

  2000cites this paper
• Efficacy of Amphotericin B Colloidal Dispersion in the Treatment of Mediterranean Visceral Leishmaniasis in Immunocompetent Adult Patients

  2000cites this paper
• Comparative Pharmacokinetics, Tissue Distributions, and Effects on Renal Function of Novel Polymeric Formulations of Amphotericin B and Amphotericin B-Deoxycholate in Rats

  2000cites this paper
• The Cured Immune Phenotype Achieved by Treatment of Visceral Leishmaniasis in the BALB/c Mouse with a Nonionic Surfactant Vesicular Formulation of Sodium Stibogluconate Does Not Protect against Reinfection

  1999cites this paper
• In vitro and in vivo activity of amphotericin B-lipid formulations against experimental Trypanosoma cruzi infections.

  1999cites this paper
• Flow cytometric assessment of amphotericin B susceptibility in Leishmania infantum isolates from patients with visceral leishmaniasis.

  1999cites this paper
• Efficacious Treatment of Experimental Leishmaniasis with Amphotericin B-Arabinogalactan Water-Soluble Derivatives

  1999cites this paper
• Antifongiques

  1999cites this paper
• Changing patterns of disease and treatment of opportunistic parasitic infections in patients with AIDS.

  1998cites this paper
• Biopharmaceutics: Comparison of the Efficacy of Free and Non‐ionic‐surfactant Vesicular Formulations of Paromomycin in a Murine Model of Visceral Leishmaniasis

  1998cites this paper
• Lipid Formulations of Amphotericin

  1998cites this paper
• Visceral Leishmaniasis in the BALB/c Mouse: A Comparison of the Efficacy of a Nonionic Surfactant Formulation of Sodium Stibogluconate with Those of Three Proprietary Formulations of Amphotericin B

  1998cites this paper
• Improvement of the Antimicrobial Activity of Moxifloxacin Using W/O Microemulsion System for Skin Infections

  year unknowncites this paper